Physician profile
Yoandy Perez
NPI 1023633153
$2,436.29
in general payments reported to CMS, 2019-2025
14 companies · $612 in 2025
The $612 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $483 · 2023: $285 · 2024: $711 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $919.20 | 2021-2024 | Ffrangio, Onyx Frontier |
| Janssen Biotech, INC. | $557.71 | 2021-2025 | Tecvayli, Darzalex, Rybrevant |
| Eisai INC. | $262.64 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $121.87 | 2025 | Cosela |
| Novartis Pharmaceuticals Corporation | $113.08 | 2021-2025 | |
| Genentech USA, INC. | $111.85 | 2024-2025 | Phesgo, Tecentriq Hybreza, Tecentriq |
| Incyte Corporation | $109.16 | 2023 | Monjuvi |
| Genmab U.S., INC. | $106.26 | 2024 | Epkinly |
| Janssen Scientific Affairs, LLC | $41.40 | 2023 | Darzalex |
| Amgen INC. | $25.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.78 | 2021 | |
| Astellas Pharma US INC | $17.30 | 2025 | Xospata |
| Boston Scientific Corporation | $15.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.95 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoandy Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.